$21.64
2.92%
Nasdaq, Aug 29, 11:38 pm CET
ISIN
US92337R1014
Symbol
VERA

Vera Therapeutics Inc - Ordinary Shares - Class A Stock price

$21.64
+0.92 4.44% 1M
-8.29 27.70% 6M
-20.65 48.83% YTD
-15.14 41.16% 1Y
-0.18 0.82% 3Y
+10.14 88.17% 5Y
+10.14 88.17% 10Y
+20.99 3,229.23% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
-0.65 2.92%
ISIN
US92337R1014
Symbol
VERA
Industry

Key metrics

Basic
Market capitalization
$1.4b
Enterprise Value
$898.8m
Net debt
positive
Cash
$556.8m
Shares outstanding
63.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.0
Financial Health
Equity Ratio
88.0%
Return on Equity
-26.4%
ROCE
-43.3%
ROIC
-
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-235.8m | $-224.4m
EBIT
$-236.1m | $-238.2m
Net Income
$-218.3m | $-285.5m
Free Cash Flow
$-186.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-101.1% | -34.3%
EBIT
-101.3% | -42.5%
Net Income
-102.4% | -87.6%
Free Cash Flow
-74.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.4
FCF per Share
$-2.9
Short interest
14.0%
Employees
192
Rev per Employee
$0.0
Show more

Is Vera Therapeutics Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Vera Therapeutics Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Vera Therapeutics Inc - Ordinary Shares - Class A forecast:

18x Buy
90%
2x Hold
10%

Analyst Opinions

20 Analysts have issued a Vera Therapeutics Inc - Ordinary Shares - Class A forecast:

Buy
90%
Hold
10%

Financial data from Vera Therapeutics Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 63 63
126% 126%
-
- Research and Development Expense 173 173
94% 94%
-
-236 -236
101% 101%
-
- Depreciation and Amortization 0.28 0.28
833% 833%
-
EBIT (Operating Income) EBIT -236 -236
101% 101%
-
Net Profit -218 -218
102% 102%
-

In millions USD.

Don't miss a Thing! We will send you all news about Vera Therapeutics Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vera Therapeutics Inc - Ordinary Shares - Class A Stock News

Neutral
GlobeNewsWire
6 days ago
BRISBANE, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present and participate in one-on-one meetings at upcoming investor conferences.
Neutral
GlobeNewsWire
24 days ago
BRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 99,000 shares of Class A common stock and restricted stock units (RSUs) underlying 48,200 shares of Class A common stock to eight...
Neutral
The Motley Fool
27 days ago
Vera Therapeutics (VERA 0.93%), a biotechnology company developing treatments for serious immunologic diseases, released results for the quarter on August 5, 2025. The most notable news was its widening net loss to $76.5 million, or $1.20 per share (GAAP), compared to analyst expectations for a GAAP loss of $0.82 per share.
More Vera Therapeutics Inc - Ordinary Shares - Class A News

Company Profile

Vera Therapeutics, Inc. is a clinical stage biotechnical company that engages in the development and commercialization of transformative treatments for immunological diseases. Its primary product, atacicept, is a fusion protein self-administered as a subcutaneous injection that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in South San Francisco, CA.

Head office United States
CEO Marshall Fordyce
Employees 192
Founded 2016
Website veratx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today